Taylor Morrison CFO Converts Options and Reports Same-Day Sale of 9,754 Shares
Rhea-AI Filing Summary
Curtis Vanhyfte, Chief Financial Officer of Taylor Morrison Home Corporation (TMHC), reported option exercises and a matched sale on 08/06/2025. He exercised employee stock options to acquire 1,501 shares at $26.28, 7,125 shares at $28.32 and 1,128 shares at $31.55, totaling 9,754 shares; the filing notes these options vested on 02/10/2024 and in two installments on 02/16/2024 and 02/16/2025.
On the same date he sold 9,754 shares at a weighted-average price of $65.22 (range $65.14–$65.48). Following these transactions the reporting person beneficially owned 14,163 shares.
Positive
- Options exercised: Acquired a total of 9,754 shares via employee stock options at exercise prices of $26.28, $28.32 and $31.55.
- Transparent pricing: Sale reported with a weighted-average price of $65.22 and a disclosed price range of $65.14–$65.48.
- Vesting disclosed: Filing notes vesting dates for the exercised options (02/10/2024 and installments on 02/16/2024 and 02/16/2025).
Negative
- Insider sale: Sold 9,754 shares on 08/06/2025, which reduced direct holdings.
- Reduced beneficial ownership: Reporting person’s holdings after the transactions are reported as 14,163 shares.
Insights
TL;DR: CFO exercised vested options and sold the resulting shares the same day, realizing proceeds at a ~$65.22 weighted-average price.
The filing shows option exercises that converted 9,754 vested option shares into common stock at exercise prices of $26.28, $28.32 and $31.55, followed by an immediate sale of those 9,754 shares at a weighted-average price of $65.22. This sequence is consistent with exercising and monetizing vested awards; the filing discloses the exact prices and the weighted-average sale range ($65.14–$65.48), and reports ending beneficial ownership of 14,163 shares. For investors, the transaction documents realization of intrinsic value from historic grants but does not, by itself, change outstanding share count or company financials.
TL;DR: Disclosure is complete on face: vesting dates, exercise prices, sale prices and post-transaction holdings are reported.
The Form 4 includes required details: transaction date (08/06/2025), exercise prices and vesting notes, the weighted-average sale price and the numerical change in beneficial ownership. The explanatory footnotes specify the weighted-average sale price range and vesting schedule for the exercised options. From a governance and compliance perspective the form appears to meet Section 16 disclosure requirements by reporting exercises and subsequent sales and providing the requested explanatory information.